It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:
Amcor (ASX: AMC)
According to a note out of Morgans, its analysts have upgraded this packaging giant's shares to a buy rating with a $15.20 price target. This follows the release of a first quarter update that was in line with expectations despite a generally subdued volume environment. It also highlights that management is becoming increasingly confident in delivering on its FY 2026 synergy targets relating to the transformational acquisition of Berry Global. And with its shares trading at around 10x forward earnings and with a 6% dividend yield, Morgans thinks that now could be a good time to invest. The Amcor share price is trading at $12.87 on Friday afternoon.
Light & Wonder Inc. (ASX: LNW)
A note out of Macquarie reveals that its analysts have retained their outperform on this gaming technology company's shares with a trimmed price target of $170.00. The broker was pleased with the company's performance in the third quarter. It highlights that Light & Wonder's adjusted EBITDA of US$375 million came in comfortably ahead of its US$360 million estimate. Macquarie points out that its revenue mix and cost management supported margin expansion across the business. Looking ahead, the broker concedes that in the near-term its ASX primary listing plans and litigation could weigh on investor sentiment, but when these issues clear in the next 6-12 months, it sees scope for a re-rating. As a result, Macquarie thinks that investors should be taking advantage of recent share price weakness. The Light & Wonder share price is fetching $125.10 at the time of writing.
Neuren Pharmaceuticals Ltd (ASX: NEU)
Analysts at Bell Potter have retained their buy rating and $25.00 price target on this pharmaceuticals company's shares. According to the note, the broker was pleased with Neuren's trading update, which revealed another solid quarter of Daybue commercialisation in the United States. The company has now received ~$45 million in royalty income across the first nine months of 2025 and Bell Potter expects this to increase to ~$64m for the full year. Outside this, it points out that its NZ-2591 product candidate is expected to start dosing its first Phase 3 trial imminently, followed by the top-line readout in ~18 to 24 months. If successful, NZ-2591 could be a very lucrative addition to its portfolio. The Neuren share price is trading at $18.46 on Friday.
